Structural basis for channel gating and blockade in tri-heteromeric GluN1-2B-2D NMDA receptor
- PMID: 39954679
- PMCID: PMC11968220
- DOI: 10.1016/j.neuron.2025.01.013
Structural basis for channel gating and blockade in tri-heteromeric GluN1-2B-2D NMDA receptor
Abstract
Discrete activation of N-methyl-D-aspartate receptor (NMDAR) subtypes by glutamate and the co-agonist glycine is fundamental to neuroplasticity. A distinct variant, the tri-heteromeric receptor, comprising glycine-binding GluN1 and two types of glutamate-binding GluN2 subunits, exhibits unique pharmacological characteristics, notably enhanced sensitivity to the anti-depressant channel blocker S-(+)-ketamine. Despite its significance, the structural mechanisms underlying ligand gating and channel blockade of tri-heteromeric NMDARs remain poorly understood. Here, we identify and characterize tri-heteromeric GluN1-2B-2D NMDAR in the adult brain, resolving its structures in the activated, inhibited, and S-(+)-ketamine-blocked states. These structures reveal the ligand-dependent conformational dynamics that modulate the tension between the extracellular domain and transmembrane channels, governing channel gating and blockade. Additionally, we demonstrate that the inhibitor (S)-DQP-997-74 selectively decouples linker tension in GluN2D, offering insights into subtype-selective targeting for cognitive modulation.
Keywords: MD simulations; channel blockade; channel gating; electrophysiology; ketamine binding site; single-particle cryo-EM; subtype-selective negative allosteric modulation; tri-heteromeric N-methyl-D-aspartate receptor.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests H.F. and S.F.T. are medical and science advisory board members for CureGRIN Foundation. S.F.T. is a medical advisory board member for the GRIN2B Foundation; a member of the scientific advisory boards for Eumentis Therapeutics and Neurocrine; a Senior Advisor for GRIN Therapeutics; a co-founder of NeurOp, Inc. and AgriThera, Inc.; and on the Board of Directors for NeurOp Inc. D.C.L. is a member of the Board of Directors for NeurOp Inc. S.P., S.F.T., and D.C.L. are coinventors on Emory-owned IP relating to NMDA receptor modulators.
References
-
- Mayer ML, Westbrook GL, and Guthrie PB (1984). Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature 309, 261–263. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources